A Post-Marketing Observational Study of VYXEOS™

CompletedOBSERVATIONAL
Enrollment

52

Participants

Timeline

Start Date

October 23, 2018

Primary Completion Date

October 26, 2019

Study Completion Date

June 12, 2020

Conditions
Acute Myeloid Leukemia With Myelodysplasia-Related ChangesTherapy-Related Acute Myeloid Leukemia
Interventions
DRUG

CPX-351

VYXEOS is administered as an intravenous (IV) infusion over approximately 90 minutes.

Trial Locations (7)

21201

University of Maryland, Baltimore

27157

Wake Forest University School of Medicine, Winston-Salem

46237

Franciscan Physician Network Oncology and Hematology Specialists, Indianapolis

63110

Washington University School of Medicine, St Louis

66205

University of Kansas Medical Center, Westwood

70112

Tulane University Hospital & Clinic, New Orleans

70121

Ochsner Clinic Foundation, New Orleans

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY